Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Recipient : Sciwind Biosciences
Deal Size : $2,470.0 million
Deal Type : Licensing Agreement
Sciwind Biosciences Signs Licensing Agreement for Metabolic Disease Portfolio
Details : Under the licensing agreement, Sciwind has granted Verdiva the exclusive global rights to develop and commercialize the partnered programs, which includes XW004 (ecnoglutide) outside of greater China.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $70.0 million
January 10, 2025
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Recipient : Sciwind Biosciences
Deal Size : $2,470.0 million
Deal Type : Licensing Agreement
Lead Product(s) : VRB-101
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Forbion
Deal Size : $411.0 million
Deal Type : Series A Financing
Verdiva Bio Launches With $410M Series A to Develop Next-Gen Therapies
Details : The financing aims to advance the clinical development of the company pipeline product, which includes VRB-101 an oral, once-weekly GLP-1 receptor agonist for obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : VRB-101
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Forbion
Deal Size : $411.0 million
Deal Type : Series A Financing
Reset All
